Institutional Profile & Quick Facts

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson provides cancer care at several locations throughout the Greater Houston Area and collaborates with health systems nationwide through MD Anderson Cancer Network®.

MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation's original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 57 National Cancer Institute-designated comprehensive cancer centers today.

U.S. News & World Report's "Best Hospitals" rankings has named MD Anderson the nation's top hospital for cancer care. The institution has been named one of the nation's top two hospitals for cancer care every year since the survey began in 1990.  

Since 1944, more than 2 million people have turned to MD Anderson for cancer care. 

MD Anderson pathologists refine a new patient's initial diagnosis by another institution up to 25% of the time.

MD Anderson's world-renowned physicians are extensively trained specialists who focus on one type of cancer and one aspect of treatment, giving them unrivaled expertise. 100% of MD Anderson's surgeons are trained in oncology compared to 30% in community hospitals. 

MD Anderson provided uninsured or underinsured Texans $346 million in uncompensated care in Fiscal Year (FY) 2024.

At MD Anderson, important scientific knowledge gained in the laboratory is rapidly translated to clinical care. 

MD Anderson is home to the world's largest cancer clinical trials program, providing patients with access to life-saving investigational drugs before they are approved by the Food and Drug Administration (FDA). 

MD Anderson receives millions of dollars in grant funding from the Cancer Prevention Research Institute of Texas (CPRIT) for research, prevention, recruitment and training. MD Anderson received almost $50 million in funding from CPRIT in FY24.

MD Anderson holds five National Cancer Institute Specialized Programs of Research Excellence (SPORE) grants in hepatocellular carcinoma, melanoma, gastrointestinal, ovarian and brain cancers and one joint SPORE grant with UTSW in lung cancer.